PEIJIA-B (09996) has successfully completed the first compassionate treatment using the TaurusTrioTM TAVR system in Hong Kong, China.
Peijia Medical-B (09996) announced that the board of directors of the company is pleased to announce that recently, the group has used for the treatment of symptomatic...
PEIJIA-B (09996) announces that the company's Board of Directors is pleased to announce that the company's product TaurusTrio, used for the treatment of symptomatic severe aortic valve regurgitation (AR), has successfully completed the first compassionate use case in Hong Kong, China.
In January 2024, the company completed patient enrollment in the multicenter registered clinical trial for the TaurusTrio TAVR system in China. Follow-up assessments in the subsequent phases are currently ongoing. The company anticipates commercializing this product in China upon regulatory approval to meet the unmet needs of a large number of AR patients.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
